Shanghai Haixin Group's subsidiary, Vitamin B6 Injection, passed the generic drug consistency evaluation.

Shanghai Haixin Group (600851.SH) announced that its holding subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. (referred to as Gannan Haixin), recently obtained the "Drug Supplementary Application Approval Notice" for the chemical drug "Vitamin B6 Injection" issued by the National Medical Products Administration. The drug passed the evaluation for consistency in quality and efficacy as a generic drug. The approval of Vitamin B6 Injection through the evaluation for consistency in quality and efficacy as a generic drug will help enhance the market competitiveness of Gannan Haixin's products and accumulate experience for its future new drug development.